Pharmaprocess Project presentation

BIONURE PROJECT PRESENTATION

  • Invitation to the Bionure Project Presentation

Bionure is a drug development company developing first-in-class therapies for the treatment of rare ophthalmological diseases. They focus in particular in two orphan diseases that cause vision loss: acute optic neuritis (AON) and neuromyelitis optica (NMO). Their lead candidate BN201 has been granted orphan designation by EMA and FDA and has shown compelling evidence of neuroprotective and remyelinating activity in several animal models. It has obtained CTA approval to start Phase 1 in the Netherlands and is in the process of obtaining IND clearance in the US. The company plans to start Phase 1 trials in 2016 and obtain an early clinical proof of concept in AON in early 2018, after Phase 2 completion. Bionure has been founded in 2015 by the US National Multiple Sclerosis Society, the leading patient advocacy group for MS.

  • Date: 28.10.2015
  • Time: 09:00
  • Place: Sala VIP- Hall 5 –  Plaza España Fira Barcelona Venue
 

MIND THE BYTE PROJECT PRESENTATION

  • Invitation to Mind the Byte Project Presentation

Mind the Byte is a bioinformatics company specializing in computational drug discovery using a pay-per-use SaaS platform (software as a service). We work with over 30 biotechnology, pharmaceutical and veterinary companies as well as research centres and universities around the world to help them complete their R&D processes more quickly and economically. This means that we can get new medicines to treat cancer, Alzheimer's, diabetes and a variety of rare diseases, among others, to patients faster. We are Amazon Web Services technology partners – a seal of quality that has only been awarded to five companies in this sector – and members of the Microsoft BizSpark Plus programme.

Mind the Byte was founded in 2011 by Alfons Nonell-Canals (@alfonsnic), who holds a PhD in Computational Chemistry and is a specialist in computer-aided drug design, in the development of software to modify active compounds, and in large-scale chemical and biological analyses. His motivation for founding the company was his desire to ensure that everyone has access to the medications they need. We are participating in a FP7 European project and we have been granted by European Comisison with a SME-Instrument Phase I project.

We've taken part in several excellence programmes, including the AWS Start-up Challenge, BioEmprenedorXXI, TEA by ACCIÓ and IESE, and Start-Up Catalonia.

  • Date: 28.10.2015
  • Time: 09:00
  • Place: Sala VIP- Hall 5 –  Plaza España Fira Barcelona Venue